Last updated on May 2020

A Study of the Impact of Apremilast (CC-10004) on Quality of Life Efficacy and Safety in Subjects With Manifestations of Plaque Psoriasis and Impaired Quality of Life

Brief description of study

This is a Phase 4, multi-center, randomized, placebo-controlled, double-blind study of the impact of apremilast on quality of life, efficacy, and safety in subjects with manifestations of plaque psoriasis and impaired quality of life.

Approximately 255 subjects will be randomized 2 (apremilast):1 (placebo) in approximately 6 to 10 countries in Western Europe. Subjects will be block-randomized equally to each of the manifestations of psoriasis (scalp psoriasis, nail psoriasis, palmoplantar psoriasis, genital psoriasis, and psoriasis in visible locations). If subjects present with multiple manifestations, they will be allocated to the manifestation which is most severe, as determined by the subject.

However, all manifestations will be assessed for efficacy at each study visit.

Clinical Study Identifier: NCT03774875

Find a site near you

Start Over

Hospital General de Castello

Castellon de la Plana, Spain
  Connect »

Kantonsspital St.Gallen

St. Gallen, Switzerland
  Connect »

Barnet Hospital

Barnet, United Kingdom
  Connect »

Brighton General Hospital

Brighton, United Kingdom
  Connect »

West Suffolk Hospital

Bury Saint Edmunds, United Kingdom
  Connect »

Guys Hospital

London, United Kingdom
  Connect »

St Cadocs Hospital

Newport, United Kingdom
  Connect »

Derriford Hospital

Plymouth, United Kingdom
  Connect »

East Surrey Hospital

Redhill, United Kingdom
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.